Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00071643 · ClinicalTrials.gov registry record · NA

Preventing Post-Stroke Depression

A NA study of Depression and Cerebrovascular Accident, sponsored by Robert G. Robinson.

Completed
Registry status
NA
Development phase
201
Enrollment target
3
Study locations

NCT00071643 is a NA study of Depression and Cerebrovascular Accident that has completed, run by Robert G. Robinson. The registered enrollment target is 201 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00071643, a NA study of Depression and Cerebrovascular Accident, has completed, sponsored by Robert G. Robinson.

COMPLETED
Registry status
NA
Development phase
201 participants
Enrollment target
3
Study locations

Study Summary

This study will evaluate the effectiveness of both drug and non-drug treatments in preventing depression after a stroke.

Interventions

  • OTHER Placebo
  • DRUG Escitalopram
  • BEHAVIORAL Problem Solving Therapy

Study Locations (3)

Illinois

  • University of Chicago - Chicago

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

New York

  • Burke Rehabilitation Hospital - White Plains

Trial Details

FieldValue
Enrollment Target 201 participants
Start Date 2002-09
Est. Completion 2008-11
Phase NA

Sponsor

Robert G. Robinson

1 total trials

What the Registry Record Tells You About NCT00071643

The ClinicalTrials.gov registry entry for NCT00071643 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (74% lower). The listed sponsor is Robert G. Robinson, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00071643 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Iowa, New York.

Frequently Asked Questions

What is clinical trial NCT00071643 about?

NCT00071643 is a clinical study titled "Preventing Post-Stroke Depression". This study will evaluate the effectiveness of both drug and non-drug treatments in preventing depression after a stroke.

What is the current status of trial NCT00071643?

This trial is currently completed. It is a NA study. The enrollment target is 201 participants. The study started on 2002-09. Estimated completion is 2008-11.

What conditions does trial NCT00071643 study?

This clinical trial studies the following conditions: Depression, Cerebrovascular Accident.

What interventions are being tested in trial NCT00071643?

The interventions under investigation include: Placebo (OTHER), Escitalopram (DRUG), Problem Solving Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT00071643?

This trial is sponsored by Robert G. Robinson, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00071643 being conducted?

This trial has 3 study locations across Illinois, Iowa, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.